Traders should monitor for potential downward pressure on KALV shares, especially if this selling continues in the next reporting window. The uniformity and timing suggest pre-arranged 10b5-1 plans, but the concentration of C-suite selling may signal lack of near-term conviction.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 23 $15.56entry
- T+1 · 9mo ago +1.35%α +0.61% · $15.77
- T+5 · 9mo ago +3.21%α +2.59% · $16.06
- T+20 · 8mo ago +6.68%α +10.63% · $16.60
- T+60 · 6mo ago +71.98%α +63.73% · $26.76
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Seven executives at KalVista Pharmaceuticals, including the CEO, CFO, CMO, CDO, and CCO, exercised stock options and sold shares in the open market over a 7-day period. The total value of shares sold was approximately $396,600, with all sales occurring at $15.5668 per share. The transactions appear to be part of a coordinated post-exercise selling activity following option exercises.
Key Financial Metrics
Key Facts
- CEO Palleiko sold 10,034 shares for $156,197; exercised 23,250 shares prior to sale
- All five C-suite executives exercised in-the-money stock options between Feb 21–23
- Total open-market sales: 25,477 shares sold for $396,600 across four days
- Sales were executed at a uniform price of $15.5668, indicating planned trades
- No insider purchases were observed in the cluster
Financial Impact
$396,600 in insider selling over 7 days
Risk Factors
- Perception of insider pessimism despite possible pre-arranged plans
- Potential for follow-on selling if 10b5-1 plans are ongoing
- Lack of offsetting insider buying during a period of material activity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (13 trades, 7d window) | cluster-KALV-1772017264193 |
Track record
12 reports on KALV
3 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +4.15% at T+5 after the Apr 17, 2026 report. 3 of 5 went positive at some point.
Filters
- Jun 22, 202621w ago 15-12G Bearish 7/10 No price data
- Jun 17, 202621w ago EFFECT Neutral 3/10 Entry $27.00 No price data
- Jun 11, 202622w ago 8-K Neutral 5/10 Entry $26.99 No price data
- Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $27.00 No price data
- May 19, 202625w ago Insider Cluster Bearish 5/10 Entry $26.81 to $26.79 ▲ +0.07% +1.31% vs SPY
- May 19, 202625w ago Insider Cluster Neutral 2/10 Entry $26.81 to $26.79 ▼ −0.07% −1.31% vs SPY
- Apr 29, 202628w ago 8-K Bullish 8/10 Entry $26.67 to $26.71 ▲ +0.15% −2.96% vs SPY
- Apr 17, 202630w ago Insider Cluster Bearish 6/10 Entry $20.48 to $19.63 ▲ +4.15% +4.71% vs SPY
- Feb 23, 202638w ago Insider Cluster Bearish 6/10 Viewing Entry $15.56 to $16.06 ▼ −3.21% −2.59% vs SPY
- Feb 23, 202638w ago Insider Cluster Bearish 7/10 Entry $15.56 to $16.06 ▼ −3.21% −2.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers